Analysts' Actions: AAPL DELL IRWD K SEE FB

NEW YORK (TheStreet) -- CHANGE IN RATINGS:

Apple (AAPL) was downgraded at Pacific Crest to sector perform. High end of the market appears saturated, Pacific Crest said. Estimates also cut.

Cascade Bancorp (CACB) was upgraded to hold at TheStreet Ratings.

Dell (DELL) was downgraded at Argus from buy to hold. Stock has already made a big run on takeover speculation, Argus said.

Ironwood Pharmaceutical (IRWD) was downgraded at UBS to sell from neutral. $11.50 price target. Expectations too high, UBS said.

Ironwood Pharmaceuticals was downgraded to sell at TheStreet Ratings.

Intermune (ITMN) was upgraded at UBS to buy from neutral. $15 price target. Short-term hurdles removed, UBS said.

Kellogg (K) was downgraded at Credit Suisse from neutral to underperform. Valuation call, based on a $55 price target, Credit Suisse said.

Mead Johnson (MJN) was downgraded at Credit Suisse from outperform to neutral. Estimates were also cut, given lower expected sales growth, Credit Suisse said. $76 price target.

Sealed Air (SEE) was upgraded at Citigroup to buy from neutral. $22 price target. Operational improvement under an aggressive new leadership, Citi said.

Valmont (VMI) was initiated with a neutral rating at Wedbush. $160 price target. Valuation call, as the stock is up 47% over the past year, Wedbush said.

Whiting Petroleum (WLL) was upgraded at Sterne Agee to buy. $62 price target. Company is looking to raise cash for acquisitions, to pay down debt or to offer a dividend, Sterne Agee said.

STOCK COMMENTS / EPS CHANGES

Apple (AAPL) estimates, target cut at BofA/Merrill. AAPL estimates were reduced through 2015, Bank of America/Merrill Lynch said. Company is facing increased smartphone competition. Buy rating and new $630 price target.

Atmel (AMTL) estimates, target raised at Canaccord. Shares of ATML now seen reaching $8, according to Canaccord Genuity. Estimates also increased, given higher netbook touch penetration. Buy rating.

Boeing (BA) cut from Conviction Buy List at Goldman. 787 risks continue to mount. $90 price target.

Bristol Myers Squibb (BMY) numbers raised at Jefferies. Shares of BMY now seen reaching $39, Jefferies said. Estimates also raised on big year for clinical trial results. Buy rating.

Eaton Vance (EV) numbers increased at BMO. EV estimates were raised through 2014, BMO Capital said. Company is attracting more assets. Market Perform rating and new $32 price target.

Express (EXPR) estimates, target upped at BMO. EXPR estimates were boosted through 2013, BMO Capital said. Company saw higher demand throughout the holidays. Outperform rating and new $19 price target.

Facebook (FB) target boosted at BofA/Merrill to $35. New advertising formats and mobile traction should continue to drive revenue acceleration. Buy rating.

Google (GOOG) estimates lowered at Canaccord through 2014, Canaccord Genuity said. Expect lower Nexus margins and higher acquisition costs. Buy rating and $810 price target.

Lululemon (LULU) estimates, target cut at Credit Suisse. Shares of LULU now seen reaching $79, according to Credit Suisse. Estimates also reduced, given moderating comp sales. Neutral rating.

Marathon Oil (MRO) numbers raised at Oppenheimer. Shares of MRO now seen reaching $40, Oppenhiemer said. Estimates also raised on improved outlook. Outperform rating.

Pfizer (PFE) numbers raised at Jefferies. Shares of PFE now seen reaching $31, Jefferies said. Estimates also raised on big year for clinical results. Buy rating.

>To submit a news tip, email: [e-mail].

READERS ALSO LIKE:

>>5 Insurance Stocks That Sandy Didn't Blow Away

>>Jim Cramer's 10 Lucrative Themes for 2013

Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.